SDC1 and neoplasm: Chandran et al.125 reported that syndecan-1 found in plasma EVs can be used to distinguish low-grade glioma from high-grade GBM with a sensitivity of 71% and a specificity of 80%, and provided strong support for plasma–EV-derived syndecan-1 being derived from GBM tumours.